Ovulation Induction Therapy
Tarizole
2.5mg (Letrozole USP)
Price on request
Formulated to support fertility treatment and reproductive health management.
About This Product
Tarizole (Letrozole USP) 2.5mg is used for ovulation induction and reproductive health management. Studies show clear advantages of Letrozole over Clomiphene Citrate, including a shorter half-life and fewer risks of multiple gestation and miscarriage.
Key Benefits
- Short half-life (2 days) compared to Clomiphene Citrate (14 days)
- Less chance of multiple gestation
- Less chance of miscarriage
- Does not decrease endometrial thickness
Composition
| Letrozole (USP) | 2.5mg |
Studies have shown clear advantages of Letrozole over Clomiphene Citrate
| Tarizole (Letrozole) | Clomiphene Citrate |
|---|---|
| Short half-life (2 days) | Long half-life (14 days) |
| Less chances of multiple gestation | More chances of multiple gestation |
| Less chances of miscarriage | More chances of miscarriage |
| Doesn't decrease endometrial thickness | Decreases endometrial thickness |
Indications & Dosage
| Condition | Dose | Duration |
|---|---|---|
| Ovulation Induction (Infertility) | 2.5mg | Day 3 - Day 7 of menstrual cycle |
| Polycystic Ovarian Syndrome | 2.5mg - 5mg | 3 - 6 months |
| Endometriosis | 5mg | 3 - 6 months |
| Uterine Fibroids | 2.5mg | 3 - 6 months |
| Male Infertility | 2.5mg | 3 - 6 months |
Recommended Use
As advised by your physician, based on condition (see dosage table).
Interested in this product?
Reach out to our team for clinical inquiries, pricing, or partnership opportunities.